MohamedAhmed Babikir Bealy

Dr. MohamedAhmed Babikir Bealy

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
MBMohamedAhmed Babikir Bealy
MohamedAhmed Babikir Bealy
AAAwad Aljeed Abugooda
Awad Aljeed Abugooda
RARuba Mustafa Elsaid Ahmed
Ruba Mustafa Elsaid Ahmed
NKNuha Abdel Rahman Khalil
Nuha Abdel Rahman Khalil
Abdelbaset Mohamed ElasbaliAbdelbaset Mohamed Elasbali
Abdelbaset Mohamed Elasbali
HAHussain Ahmed
Hussain Ahmed
Objective. This study aimed to associate the expression of P53, BCL2, PTEN, and HER2/neu tumor markers in specific breast cancer lesions. Methods. This study analyzed the immunohistochemical expression of P53, BCL2, PTEN, and HER2/neu tumor markers for 306 patients who presented with lesions. Tissue blocks and patients identification data were retrieved from the department of pathology, AL Madinah Almonwarah hospital, Al Madinah, UAE. Results. Of the 306 patients, 104 had benign lesions and 202 had malignancy (including 194 females and 6 males). Most females were presented with invasive ductal carcinoma (IDC), followed by infiltrating ductal carcinoma, and invasive lobular carcinoma (ILC), representing 70, 23.2, and 3.7, respectively. Positive P53, BCL2, PTEN, and HER2 were identified in 20.8, 11.9, 91, and 18.3, respectively. Conclusion: The expression of P53, BCL2, PTEN, and HER2/neu tumor markers among Saudi patients with breast cancer is relatively similar in many parts of the world.